Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Biomerica (BMRA) over the last 15 years, with Q4 2025 value amounting to $1.6 million.

  • Biomerica's Total Current Liabilities fell 1476.55% to $1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was $1.6 million, marking a year-over-year decrease of 1476.55%. This contributed to the annual value of $1.7 million for FY2025, which is 2105.26% down from last year.
  • Per Biomerica's latest filing, its Total Current Liabilities stood at $1.6 million for Q4 2025, which was down 1476.55% from $1.7 million recorded in Q3 2025.
  • Biomerica's 5-year Total Current Liabilities high stood at $6.7 million for Q1 2022, and its period low was $1.3 million during Q2 2021.
  • Over the past 5 years, Biomerica's median Total Current Liabilities value was $1.8 million (recorded in 2022), while the average stood at $2.1 million.
  • As far as peak fluctuations go, Biomerica's Total Current Liabilities skyrocketed by 39540.54% in 2022, and later plummeted by 7917.1% in 2023.
  • Over the past 5 years, Biomerica's Total Current Liabilities (Quarter) stood at $4.7 million in 2021, then crashed by 62.81% to $1.8 million in 2022, then grew by 3.33% to $1.8 million in 2023, then increased by 2.96% to $1.9 million in 2024, then dropped by 14.77% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q4 2025, $1.7 million for Q3 2025, and $1.7 million during Q2 2025.